{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:43:54Z","timestamp":1794278634902,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.chest.2024.05.015","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T19:49:02Z","timestamp":1717876142000},"page":"1124-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-1601","authenticated-orcid":false,"given":"Shota","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0115-2615","authenticated-orcid":false,"given":"Johsuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8383-9504","authenticated-orcid":false,"given":"Mao","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-9477","authenticated-orcid":false,"given":"Yoshihiro","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-2516","authenticated-orcid":false,"given":"Yu","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7403","authenticated-orcid":false,"given":"Yasushi","family":"Obase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-307X","authenticated-orcid":false,"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-4760","authenticated-orcid":false,"given":"Akio","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.chest.2024.05.015_bib1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/thx.2006.060087","article-title":"Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms","volume":"61","author":"Ford","year":"2006","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.chest.2024.05.015_bib2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1183\/09031936.00218714","article-title":"The global epidemiology of chronic cough in adults: a systematic review and meta-analysis","volume":"45","author":"Woo-Jung","year":"2015","journal-title":"Eur Respir J"},{"issue":"162","key":"10.1016\/j.chest.2024.05.015_bib3","doi-asserted-by":"crossref","first-page":"210127","DOI":"10.1183\/16000617.0127-2021","article-title":"Chronic cough: new insights and future prospects","volume":"30","author":"Morice","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"1 suppl","key":"10.1016\/j.chest.2024.05.015_bib4","doi-asserted-by":"crossref","first-page":"220s","DOI":"10.1378\/chest.129.1_suppl.220S","article-title":"Unexplained (idiopathic) cough: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Pratter","year":"2006","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2024.05.015_bib5","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaip.2019.04.012","article-title":"What is chronic cough? Terminology","volume":"7","author":"McGarvey","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1378\/chest.15-1496","article-title":"Treatment of unexplained chronic cough: CHEST guideline and expert panel report","volume":"149","author":"Gibson","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2024.05.015_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00424-006-0070-9","article-title":"Pharmacology of P2X channels","volume":"452","author":"Gever","year":"2006","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"9974","key":"10.1016\/j.chest.2024.05.015_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","article-title":"P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study","volume":"385","author":"Abdulqawi","year":"2015","journal-title":"Lancet"},{"issue":"10328","key":"10.1016\/j.chest.2024.05.015_bib10","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","article-title":"Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials","volume":"399","author":"McGarvey","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2024.05.015_bib11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.alit.2022.05.006","article-title":"A\u00a0phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough","volume":"71","author":"Niimi","year":"2022","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.chest.2024.05.015_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00408-023-00606-w","article-title":"The efficacy and safety of gefapixant in a phase 3b trial of patients with recent-onset chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.chest.2024.05.015_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11302-022-09877-z","article-title":"ATP, an attractive target for the treatment of refractory chronic cough","volume":"18","author":"Zhang","year":"2022","journal-title":"Purinergic Signal"},{"issue":"suppl 65","key":"10.1016\/j.chest.2024.05.015_bib14","article-title":"Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC)","volume":"58","author":"Birring","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2024.05.015_bib15","first-page":"A5608","article-title":"Improvements in cough severity and quality of life in SOOTHE, a phase 2b, dose finding trial of BLU-5937 in refractory chronic cough","volume":"205","author":"Birring","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2024.05.015_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04240-2020","article-title":"Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study","volume":"58","author":"Morice","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.05.015_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","article-title":"Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study","volume":"201","author":"Dicpinigaitis","year":"2023","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12931-023-02384-8","article-title":"The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial","volume":"24","author":"Friedrich","year":"2023","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.chest.2024.05.015_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00725-2021","article-title":"Randomised trial of the P2X(3) receptor antagonist sivopixant for refractory chronic cough","volume":"59","author":"Niimi","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A\u00a0randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"issue":"13","key":"10.1016\/j.chest.2024.05.015_bib21","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/bph.14677","article-title":"Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in\u00a0vivo efficacy in models of sensitisation","volume":"176","author":"Richards","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99177-0","article-title":"Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers","volume":"11","author":"Davenport","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.chest.2024.05.015_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128384","article-title":"Discovery of clinical candidate Sivopixant (S-600918): lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists","volume":"52","author":"Kai","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.chest.2024.05.015_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","article-title":"BLU-5937: a selective P2X3 antagonist with potent anti-tussive effect and no taste alteration","volume":"56","author":"Garceau","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"issue":"34","key":"10.1016\/j.chest.2024.05.015_bib25","doi-asserted-by":"crossref","first-page":"11890","DOI":"10.1523\/JNEUROSCI.0698-12.2012","article-title":"Differential expression and pharmacology of native P2X receptors in rat and primate sensory neurons","volume":"32","author":"Serrano","year":"2012","journal-title":"J\u00a0Neurosci"},{"issue":"2","key":"10.1016\/j.chest.2024.05.015_bib26","doi-asserted-by":"crossref","first-page":"00007","DOI":"10.1183\/23120541.00007-2023","article-title":"Variability in P2X receptor composition in human taste nerves: implications for treatment of chronic cough","volume":"9","author":"High","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.chest.2024.05.015_bib27","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.chest.2024.05.015_bib28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.chest.2024.05.015_bib29","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019"},{"issue":"2","key":"10.1016\/j.chest.2024.05.015_bib30","article-title":"Performance of a digital signal processing algorithm for the accurate quantification of cough frequency","volume":"58","author":"Jaclyn","year":"2021","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.chest.2024.05.015_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/psp4.12091","article-title":"Model-based network meta-analysis: a framework for evidence synthesis of clinical trial data","volume":"5","author":"Mawdsley","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.chest.2024.05.015_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1343","article-title":"From bench to bedside: the role of cough hypersensitivity in chronic cough","volume":"13","author":"Drake","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.chest.2024.05.015_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.chest.2024.05.015_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.chest.2024.05.015_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00408-022-00587-2","article-title":"Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough","volume":"200","author":"Schelfhout","year":"2022","journal-title":"Lung"},{"key":"10.1016\/j.chest.2024.05.015_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211049743","article-title":"Validation of a visual analog scale for assessing cough severity in patients with chronic cough","volume":"15","author":"Martin Nguyen","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.chest.2024.05.015_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221099737","article-title":"Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough","volume":"16","author":"Nguyen","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00439-2019","article-title":"The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study","volume":"54","author":"Morice","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2024.05.015_bib39","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01615-2019","article-title":"Gefapixant in two randomised dose-escalation studies in chronic cough","volume":"55","author":"Smith","year":"2020","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.chest.2024.05.015_bib40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","article-title":"Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial","volume":"8","author":"Smith","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2024.05.015_bib41","first-page":"A5778","article-title":"Safety and efficacy of BLU-5937 in the\u00a0treatment of refractory chronic cough from the phase 2b soothe trial","volume":"205","author":"Smith","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.05.015_bib42","first-page":"A2533","article-title":"Response in patient-reported cough severity in soothe, a phase 2b trial of camlipixant in refractory chronic cough","volume":"207","author":"McGarvey","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"14","key":"10.1016\/j.chest.2024.05.015_bib43","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2023.18035","article-title":"Efficacy and tolerability of gefapixant for treatment of refractory or unexplained chronic cough: a systematic review and dose-response meta-analysis","volume":"330","author":"Kum","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.chest.2024.05.015_bib44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1164\/rccm.202211-2128LE","article-title":"Efficacy and safety of gefapixant for refractory or unexplained chronic cough over 52\u00a0weeks","volume":"207","author":"Birring","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2024.05.015_bib45","first-page":"A2532","article-title":"Randomized proof-of-concept study of AX-8, a TRPM8 agonist, in refractory or unexplained chronic cough","volume":"207","author":"Hull","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2024.05.015_bib46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","article-title":"The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1)","volume":"157","author":"Smith","year":"2020","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.chest.2024.05.015_bib47","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1111\/bph.15531","article-title":"Inhibition of inflammatory pain and cough by a novel charged sodium channel blocker","volume":"178","author":"Tochitsky","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.chest.2024.05.015_bib48","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01452-2016","article-title":"Tussive challenge with ATP and AMP: Does it reveal cough hypersensitivity?","volume":"49","author":"Fowles","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2024.05.015_bib49","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201911-2263OC","article-title":"Increased capsaicin sensitivity in patients with severe asthma is associated with worse clinical outcome","volume":"201","author":"Kanemitsu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2024.05.015_bib50","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1164\/rccm.201508-1602OC","article-title":"Neurophenotypes in airway diseases. Insights from translational cough studies","volume":"193","author":"Belvisi","year":"2016","journal-title":"Am J Respir Crit Care Med"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369224006937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T18:33:56Z","timestamp":1733337236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369224006937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0012369224006937"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2024.05.015","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2024.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}